Enpatoran

N/A

Report date: 2026/05/22 20:01:29
NME

Base Information

Drug NameEnpatoran
Drug Alias NameM-5049
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionImmunologic receptors antagonistsToll like receptor 7 antagonistsToll like receptor 8 antagonists
TargetsImmunologic receptorsToll like receptor 7Toll like receptor 8
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Lupus Erythematosus, SystemicLupus Erythematosus, Cutaneous +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[35] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesMerck & Co Inc
China Registration ClassN/A

Develop Information

Active CompaniesMerck Healthcare Kgaa, Darmstadt, Germany, An Affiliate Of Merck Kgaa, Darmstadt, GermanyEmd Serono Research & Development Institute IncR-Pharm Germany Gmbh +[7] 
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Lupus Erythematosus, SystemicLupus Erythematosus, Cutaneous +[4] 
Inactive IndicationsDermatomyositisPolymyositis

Other Information

ATC CodeN/A
Related LinksN/A